Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (193)

61

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer : final survival analysis of the ADEBAR study

enthalten in: British journal of cancer | 2016

von Janni, W. | Harbeck, N. | Rack, B. | +9

62

Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer : a post hoc analysis of the MRC COIN study

enthalten in: British journal of cancer | 2016

von Grenader, T. | Nash, S. | Adams, R. | +4

63

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

enthalten in: British journal of cancer | 2016

von Zielinski, C. | Lang, I. | Beslija, S. | +7

64

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer

enthalten in: British journal of cancer | 2015

von Lim, S. | Kim, T. | Hong, Y. | +14

65

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer

enthalten in: British journal of cancer | 2015

von Rees, J. | Hurt, C. | Gollins, S. | +14

66

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

enthalten in: British journal of cancer | 2015

von Beije, N. | Kraan, J. | Taal, W. | +12

67

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel

enthalten in: British journal of cancer | 2015

von Langer, C. | Hirsh, V. | Okamoto, I. | +6

68

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

enthalten in: British journal of cancer | 2015

von Weickhardt, A. | Williams, D. | Lee, C. | +12

69

Assessing the benefit-risk of new treatments using generalised pairwise comparisons : the case of erlotinib in pancreatic cancer

enthalten in: British journal of cancer | 2015

von Péron, J. | Roy, P. | Ding, K. | +3

70

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

enthalten in: British journal of cancer | 2015

von Price, T. | Bruhn, M. | Lee, C. | +12